Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4766-4777

  Van Wart, Scott ^a   Phillips, Luann ^a   Ludwig, Elizabeth A ^a   Russo, Rene ^b   Gajjar, Diptee A ^b   Bello, Akintunde ^b   Ambrose, Paul G ^a   Costanzo, Christopher ^a   Grasela, Thaddeus H ^a   Echols, Roger ^b   Grasela, Dennis M ^b  

^a Albany Medical College   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GARENOXACIN; PSEUDOEPHEDRINE;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; BAYES THEOREM; BODY WEIGHT; CALCULATION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GENDER; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BINDING; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BRONCHITIS; COMMUNITY-ACQUIRED INFECTIONS; DRUG INTERACTIONS; FEMALE; FLUOROQUINOLONES; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MODELS, BIOLOGICAL; PNEUMONIA; POPULATION; REPRODUCIBILITY OF RESULTS; RESPIRATORY TRACT INFECTIONS; SINUSITIS;

EID: 9644273975     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4766-4777.2004     Document Type: Article

References (33)

1. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolone against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2997.
2. American Society of Health-System Pharmacists, Inc. 2002. American hospital formulary service drug information, p. 1304. Bethesda, Md.
3. American Thoracic Society. 1993. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am. Rev. Respir. Dis. 1481418-1426.
4. Bayer Corporation. 2001. Avelox (moxifloxacin) product information. Bayer Corporation, West Haven, Conn.
5. Celli, B. R., G. L. Snider, J. Heffner, et al. 1995. American Thoracic Society statement - standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 152:S77-S120.
6. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
8. Craig, W.A. 2002. Pharmacodynamics of antimicrobials: general concepts and applications, p. 10. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.). Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, Inc., New York, N.Y.
9. Dionne, R. E., L. A. Bauer, G. A. Gibson, W. O. Griffen, and R. A. Blouin. 1981. Estimating creatinine clearance in morbidly obese patients. Am. J. Hosp. Pharm. 38:841-844.
10. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Stadiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
11. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
12. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.
13. Gajjar, D. A., A. Bello, Z. Ge, L. Christopher, D. M. Grasela. 2003. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother. 47:2256-2263.
14. Gajjar, D. A., S. C. Sukoneck, A. Bello, Z. Ge, L. Christopher, and D. M. Grasela. 2002. Effect of a high fat meal on the pharmacokinetics of the des-6(F) quinolone BMS-284756. Pharmacotherapy 22:160-165.
15. Gibaldi, M., D. Perrier. 1982. Pharmacokinetics, 2nd edition. Marcel Dekker, Inc., New York, N.Y.
16. Heyd, A., and D. Haverstock. 2000. Retrospective analysis of the safety profile of oral and intravenous ciprofloxacin in a geriatric population. Clin. Ther. 22:1239-1250.
17. Hoellman, D. B., L. M. Kelly, M. R. Jacobs, and P. C. Applebaum. 2001. Comparative antianaerobic activity of BMS-284756. Antimicrob. Agents Chemother. 45:586-592.
18. Lacy, M. A., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43672-677.
19. Lesko, L. J., M. Rowland, C. C. Peck, and T. F. Blaschke. 2000. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm. Res. 17:1335-1344.
20. 0-24/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J. Antimicrob. Chemother. 51:199-202.
21. Lister, P. D. 2002. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob. Agents Chemother. 46:69-74.
22. Lister, P. D., and C. C. Sanders. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. 1999. J. Antimicrob. Chemother. 43:79-86.
23. Matzke, G. R., and S. P. Millikin. 1992. Influence of renal function and dialysis on drug disposition, p. 1-49. In W. J. Jusko, W. E. Evans, and J. J. Schentag (ed.), Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics, Inc., Vancouver, Wash.
24. Michalets, E. L. 1998. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
25. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing. Standard M100-S8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Nicolau, D. P., H. M. Mattoes, M. Banevicius, D. Xuan, C. H. Nightingale. 2003. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob. Agents Chemother. 47:1630-1635.
27. Noel, G. J., J. Natarajan, S. Chien, T. L. Hunt, D. B. Goodman, R. Abels. 2003. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin. Pharmacol. Ther. 73:292-303.
28. NONMEM Project Group. 1994. Part 5, p. 138-139. In S. L. Beal and L. B. Sheiner (ed.), NONMEM user's guide. University of California at San Francisco.
29. Ozdemir, V., J. Fourie, U. Busto, and C. A. Naranjo. 1996. Pharmacokinetic changes in the elderly. Clin. Pharmacokinet. 31:372-385.
30. Peck, C. C., and M. G. Murphy. 1989. Bedside estimation of ideal body weight, p. 80. In C. C. Peck and M. G. Murphy (ed.), Bedside clinical pharmacokinetics: simple techniques for individualizing drug therapy. Applied Therapeutics, Inc., Vancouver, Wash.
31. Piscitelli, S.C., and K. A. Struble. 2001. Drug interactions with antiretrovirals for HIV infection, p. 40. In S. C. Piscitelli and K. A. Rodvold (ed.), Drug interactions in infectious diseases. Humana Press, Totowa, N.J.
32. Sheiner, L. B., and S. L. Beal. 1989. Scientific commentary: some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-511.
33. Stahlmann, R., and H. Lode. 2000. Safety overview: toxicity, adverse effects and drug interactions, p. 398-442. In V. Andriole (ed.), The quinolones, 3rd edition. Academic Press, San Diego, Calif.